ABSTRACT
As in cancer therapy, recently developed immunologically active agents may serve as induction therapy to gain control of an autoimmune process, allowing subsequent use of less toxic, chronically administered treatments. Acutely, they may ameliorate disease exacerbations, or "flares." Combinations of agents to specifically affect pro-inflammatory cytokine secretion, such as TNFa and IL-I may offer significant clinical benefit by intervening at several points in the inflammatory process (1).
